-
Endoso Life Raises Pre-Series A Funding for High-End Medical Endoscope Development
•
Endoso Life, a Hangzhou-based developer of high-end medical endoscope systems and devices, has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The round was led by BGI Co-Win, with participation from Findowin Capital. The proceeds will be used to support research and development of high-end…
-
Vcanbio’s VUM02 Accepted for Review by China’s Center for Drug Evaluation
•
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the clinical trial filing for its VUM02 (human umbilical cord-derived mesenchymal stem cells), a Category 1 therapeutic biologic product, has been accepted for review by the Center for Drug Evaluation. This marks a significant step forward in…
-
Fosun Pharma’s Human Interferon Gamma Approved for New Indication by NMPA
•
Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced receiving another indication approval from the National Medical Products Administration (NMPA) for its human interferon gamma for injection. The therapeutic biologic product can now be used to reduce the frequency and severity of severe infections associated with chronic granulomatosis, an indication…
-
InnoCare Pharma’s Hibruka Receives HSA Approval for Mantle Cell Lymphoma in Singapore
•
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the Health Sciences Authority (HSA) of Singapore for its Bruton’s tyrosine kinase (BTK) inhibitor Hibruka (orelabrutinib) to treat adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL). This marks a significant expansion of the drug’s…
-
Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma
•
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced plans to acquire the Marketing Authorization Holder (MAH) rights to Beijing Baiao Pharmaceuticals Co., Ltd’s generic version of Takeda Pharmaceutical Co., Ltd’s azilsartan (20mg, 40mg) for RMB 36.05 million (USD 5.04 million). The deal is structured to transfer the…
-
UB Biotechnology Secures Series A Funding for Flow Cytometry Platform
•
China-based in vitro diagnostics (IVD) maker UB Biotechnology (Zhejiang) Co., Ltd has reportedly raised “tens of millions” of renminbi in a Series A financing round, led solely by Yuanbio Venture Capital. The proceeds will be directed towards research and development and market development for its flow cytometry technology platform. Company…
-
IASO Biotherapeutics Partners with Umoja Biopharma to Evaluate iCIL Platform
•
China-based biopharma IASO Biotherapeutics has announced a research agreement with US immuno-oncology company Umoja Biopharma, Inc., to evaluate Umoja’s iCIL platform with IASO’s best-in-class chimeric antigen receptors (CARs). The collaboration aims to develop off-the-shelf therapies for patients with hematological malignancies, initially focusing on acute myeloid leukemia (AML), with the goal…
-
Shanghai Unveils Policies to Boost Global Biomedical R&D Hub
•
The Shanghai municipal government has released a set of policies and measures aimed at accelerating the establishment of Shanghai as a global biomedical R&D economy and industrialization hub. The initiative seeks to provide improved guidance for financial funding and social capital, enhancing the total economic contribution from biomedical research and…
